Clinical trials: NSCLC Adenocarcinoma
Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell…
- Conditions
- Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
- Trial name
- NCT07164313
- Testing
- ZW251
- Where
- 25 sites in United States, Ireland and 4 more
- Volunteers
- 140 people
- Sponsor
- Zymeworks BC Inc.
Breast Cancer, Kidney Cancer
Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases
RATIONALE: Genistein may increase the effectiveness of radiation therapy in treating pain caused by bone metastases. PURPOSE: This phase I/II trial is studying the side effects of genistein and to see how well it works in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer, Melanoma
- Trial name
- NCT00769990
- Testing
- genistein, radiation therapy
- Sponsor
- Masonic Cancer Center, University of Minnesota
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
The purpose of this study is to learn about the safety and effects of the study medicine when given alone or together with other anti-cancer therapies. Anti-cancer therapy is a type of treatment to stop the growth of cancer.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06704724
- Testing
- PF-07985045, Gemcitabine, Nab-paclitaxel
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 30 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung Cancer
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study
This is a nationwide, multicenter and prospective cohort study. The purpose of this study is to evaluate the synergistic effect and safety of Elemene plus TKIs in EGFR-mutated advanced non-small cell lung cancer.
- Conditions
- Carcinoma, Non-Small-Cell Lung Cancer, Adenocarcinoma
- Trial name
- SELECT-2 (NCT04401059)
- Testing
- Elemene plus first or third generation EGFR-TKIs, First or third generation EGFR-TKIs
- Where
- 7 sites in China
- Volunteers
- 744 people
- Sponsor
- Tian Xie
Lung Cancer
Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer And Lung Dysfunction
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00009789
- Testing
- accelerated conformational radiotherapy
- Where
- 20 sites in United States
- Volunteers
- 39 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Adenocarcinoma
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
This is a prospective, open, single-center, phase Ⅱ study to assess the efficacy and safety of alternating Icotinib and chemotherapy for advanced non-small cell lung cancer with EGFR mutation.
- Trial name
- NCT02737774
- Testing
- Icotinib, Pemetrexed/Carboplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Henan Cancer Hospital
Solid Tumors, Non-Small Cell Lung Cancer
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
This is a phase 1a/1b, open-label, multicenter, dose-escalation and dose-expansion study evaluating the safety, tolerability, antitumor activity, pharmacokinetics, and pharmacodynamics of FXB0871 monotherapy in adults with…
- Conditions
- Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07558200
- Testing
- Intervention1：FXB0871, Intervention2：FXB0871, Intervention3：FXB0871
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Lung Cancer
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
RATIONALE: Wedge resection or segmentectomy may be less invasive types of surgery than lobectomy for non-small cell lung cancer and may have fewer side effects and improve recovery.
- Trial name
- NCT00499330
- Testing
- lobectomy, segmentectomy or wedge resection
- Where
- 386 sites in United States, Australia and 1 more
- Sponsor
- Alliance for Clinical Trials in Oncology
Bladder Cancer, Breast Cancer
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00471432
- Testing
- custirsen sodium, docetaxel, pharmacological study
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Lung Adenocarcinoma, Neutropenia
Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy
Folic acid (FA; folate) in the dose of 350-1,000 μg daily should be supplemented, daily, starting 7 days before the first dose of pemetrexed based chemotherapy and should be continued while the patient is on therapy and for 21…
- Conditions
- Lung Adenocarcinoma, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- PEMVITASTART (NCT02679443)
- Testing
- Folate and B12
- Where
- India
- Volunteers
- 161 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC)
XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
This is a global, multi-center, open-label, Phase I/II first-in-human study of XNW27011 monotherapy as an investigational product (IP) in patients with locally advanced and/or metastatic solid tumors who have failed or are…
- Conditions
- Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic
- Trial name
- NCT06792435
- Testing
- XNW27011
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Renal Cell Cancer, Castrate Resistant Prostate Cancer
TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma
The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care.
- Conditions
- Renal Cell Cancer, Castrate Resistant Prostate Cancer, Non Small Cell Lung Cancer, Pleural Mesothelioma Malignant
- Trial name
- NCT04969315
- Testing
- TT-10, TT-4
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Portage Biotech
MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer
Evaluation of XYA02 in Patients With Advanced Solid Tumors
This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.
- Conditions
- MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma
- Trial name
- NCT07670312
- Testing
- XYA02
- Where
- 5 sites in Australia
- Volunteers
- 190 people
- Sponsor
- XYone Therapeutics, Inc
Mesothelioma, Glioblastoma
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Conditions
- Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT04913337
- Testing
- NGM707, NGM707 plus pembrolizumab (KEYTRUDA®)
- Where
- 27 sites in United States, South Korea and 1 more
- Volunteers
- 179 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non-Small Cell Lung Cancer
Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen
Erlotinib has demonstrated efficacy as a single agent in patients with NSCLC and the addition of erlotinib to chemotherapy has not achieved better results in the general population.
- Trial name
- NCT00908336
- Testing
- Docetaxel and Erlotinib, Erlotinib
- Where
- 8 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Hospital Arnau de Vilanova
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Cancer, Solid Tumor
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
Rationale: CALAA-01 is a targeted therapeutic designed to inhibit tumor growth and/or reduce tumor size. The active ingredient in CALAA-01 is a small interfering RNA (siRNA).
- Trial name
- NCT00689065
- Testing
- CALAA-01
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Calando Pharmaceuticals
Anemia, Drug/Agent Toxicity by Tissue/Organ
Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Anemia, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Neutropenia
- Trial name
- NCT00077311
- Testing
- darbepoetin alfa, pegfilgrastim, cisplatin
- Where
- 64 sites in United States
- Volunteers
- 160 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01935336
- Testing
- Ponatinib
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- University of Colorado, Denver